Loading candles…
P&G Health Ltd, formerly known as Procter & Gamble td and earlier Merck Limited, operates in the pharmaceuticals, chemicals, and consumer health industries. The company manufactures and markets pharmaceuticals, chemicals, vitamins, minerals, and supplements. After its acquisition by The Procter & Gamble Company in 2018, P&G Health Ltd has focused exclusively on the consumer health segment, particularly products related to nerve care, respiratory health, and vitamin supplements. The company holds a significant position in these therapeutic categories.
This page is a live market overview for PROCTER & GAMBLE HEALTH L (PGHL) on the NSE. As a listed security, PROCTER & GAMBLE HEALTH L is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for PGHL before placing trades on tick2trade.
As of the latest feed, PGHL last traded at ₹6,144.5 on NSE, up ₹76.5 (1.26%) from the previous close of ₹6,068. Today's session range is ₹6,009 – ₹6,170, against a 52-week band of ₹4,707 – ₹6,975. Traded volume today stands at 25.00K shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for PGHL in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether PGHL is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for PROCTER & GAMBLE HEALTH L before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in PGHL. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated PGHL option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - Q1-FY26 | To consider and approve the financial results for the quarter ended Jun 30, 2026 | 6 Aug 2026 |
| Audited Results - FY26 | To consider and approve the audited financial statements for the financial year ended March 31, 2026, and recommend final dividend, if any. | 26 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 6 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 and dividend, if any | 6 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 5 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 and dividend | 5 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 1 Aug 2025 |
| Audited Results - FY25 | To consider and approve the audited financial results for the financial year ended March 31, 2025 and recommend dividend, if any. | 29 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.